logo
Plus   Neg
Share
Email

AMETEK's Board Declares 3-for-2 Stock Split; Boosts Dividend 50% - Quick Facts

AMETEK Inc.'s (AME) board has declared a three-for-two stock split and approved a 50% increase in the quarterly cash dividend on its common stock. The three-for-two split of its common stock would result in the issuance of one additional common share for every two shares owned as of the record date. The new shares are payable on June 29, 2012, to shareholders of record on June 15, 2012.

Any fractional shares resulting from the stock split would be paid in cash based on the closing market price of AMETEK stock on the record date. By splitting its stock, AMETEK said it expects to broaden the stock's marketability and improve its trading liquidity.

Also, after reviewing the company's strong financial position and future expectations, AMETEK's board has decided to increase the quarterly dividend by 50%, to an indicated annual rate of $0.36 per share. The board declared the second quarter dividend of $.09 per share, payable on June 29, 2012 to shareholders of record on June 15, 2012.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT